Adherence to <scp>glucagon‐like peptide</scp> ‐1 receptor agonist treatment in type 2 diabetes mellitus: A nationwide registry study
Approximately one in five patients discontinued GLP-1RA therapy within the first 12 months and only half were adherent. Overall, lower socioeconomic status and higher comorbidity burden were associated with higher risk of discontinuing GLP-1RA treatment.
Authors
- Andrei‐Mircea Catarig (ORCID: https://orcid.org/0000-0002-7667-8315)
- Bodil Vistisen
- Hanan Amadid (ORCID: https://orcid.org/0000-0001-5759-4960)
- Mats Christian Højbjerg Lassen (ORCID: https://orcid.org/0000-0002-2255-582X)
- Gunnar Gislason (ORCID: https://orcid.org/0000-0002-0548-402X)
- Esther Zimmermann (ORCID: https://orcid.org/0000-0001-5854-0542)
- Daniel Modin (ORCID: https://orcid.org/0000-0002-7566-0519)
- Niklas Dyrby Johansen (ORCID: https://orcid.org/0000-0001-6959-3236)
- Tor Biering‐Sørensen (ORCID: https://orcid.org/0000-0003-4209-2778)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Novo Nordisk (Denmark) (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1111/dom.15872
- Citations
- 20
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 7.15
Funders
- Hjerteforeningen
- Novo Nordisk